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Abstract
Background: Plasma level of high-density lipoprotein-cholesterol (HDL-C), a heritable trait, is an
important determinant of susceptibility to atherosclerosis. Non-synonymous and regulatory single
nucleotide polymorphisms (SNPs) in genes implicated in HDL-C synthesis and metabolism are likely to
influence plasma HDL-C, apolipoprotein A-I (apo A-I) levels and severity of coronary atherosclerosis.
Methods: We genotyped 784 unrelated Caucasian individuals from two sets of populations (Lipoprotein
and Coronary Atherosclerosis Study- LCAS, N = 333 and TexGen, N = 451) for 94 SNPs in 42 candidate
genes by 5' nuclease assays. We tested the distribution of the phenotypes by the Shapiro-Wilk normality
test. We used Box-Cox regression to analyze associations of the non-normally distributed phenotypes
(plasma HDL-C and apo A-I levels) with the genotypes. We included sex, age, body mass index (BMI),
diabetes mellitus (DM), and cigarette smoking as covariates. We calculated the q values as indicators of
the false positive discovery rate (FDR).
Results: Plasma HDL-C levels were associated with sex (higher in females), BMI (inversely), smoking
(lower in smokers), DM (lower in those with DM) and SNPs in APOA5, APOC2, CETP, LPL and LIPC (each q
≤0.01). Likewise, plasma apo A-I levels, available in the LCAS subset, were associated with SNPs in CETP,
APOA5, and APOC2 as well as with BMI, sex and age (all q values ≤0.03). The APOA5 variant S19W was also
associated with minimal lumen diameter (MLD) of coronary atherosclerotic lesions, a quantitative index
of severity of coronary atherosclerosis (q = 0.018); mean number of coronary artery occlusions (p =
0.034) at the baseline and progression of coronary atherosclerosis, as indicated by the loss of MLD.
Conclusion: Putatively functional variants of APOA2, APOA5, APOC2, CETP, LPL, LIPC and SOAT2 are
independent genetic determinants of plasma HDL-C levels. The non-synonymous S19W SNP in APOA5 is
also an independent determinant of plasma apo A-I level, severity of coronary atherosclerosis and its
progression.
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Coronary artery disease is the most common cause of
death in the western hemisphere and is expected to
become the leading cause of morbidity and mortality in
the world by the year 2020 [1]. Plasma high-density lipo-
protein-cholesterol (HDL-C) level is a major determinant
of susceptibility to coronary atherosclerosis in the general
population [2-7]. A low plasma HDL-C level is the most
common lipid abnormality found in families with prema-
ture coronary atherosclerosis [2]. Plasma HDL-C level is
inversely associated with the progression of coronary
atherosclerosis and cardiovascular mortality [3-7]. In con-
trast, raising the plasma high HDL-C level, even modestly,
with the exception of inhibition of cholesteryl ester trans-
fer protein (CETP) with torcetrapib, protects against
atherosclerosis and reduces adverse cardiovascular events
[4,8-10].
Genetic studies of Mendelian traits have firmly estab-
lished the impact of genetic mutations on plasma HDL-C
levels. A prototypic example is Tangier disease, wherein
mutations in ABCA1 lead to very low plasma HDL-C and
apolipoprotein (apo) A-I levels and premature coronary
atherosclerosis [11,12]. Plasma HDL-C level in the general
population is also a heritable trait. Heritability of plasma
HDL-C level has been estimated to be greater than 50% in
most studies [13-18]. The estimates of heritability in the
Strong Heart Family Study and HERITAGE family study
were 50% and 52%, respectively [14,15]. Unlike the Men-
delian disorders, however, the specific genetic variants
that contribute to plasma HDL-C levels in the general
population are largely unknown. The advent of genome-
wide association studies (GWAS) has raised considerable
interest in identifying novel genetic determinants of com-
plex traits, such as plasma HDL-C. Accordingly, several
genes that influence plasma HDL-C levels have been iden-
tified [19,20]. Collectively, the associated variants in
GWAS accounted for only 5-8% of the variation in the
plasma HDL-C levels [19,20]. Hence, much of the herita-
bility of plasma HDL-C levels has remained unexplained.
We genotyped 784 unrelated Caucasian individuals from
two independent populations of Lipoprotein and Coro-
nary Atherosclerosis Study (N = 333) and TexGen (N =
451) for 94 non-synonymous or regulatory single nucle-
otide polymorphisms (SNPs) in 42 genes implicated in
HDL-C biosynthesis and metabolism. We analyzed asso-
ciation of the SNPs with plasma HDL-C and apo A-I levels
as well as with the severity and progression of coronary
atherosclerosis.
Methods
Study population
All participants signed informed consent for the genetic
studies and the institutional review board approved the
study. We include 784 unrelated Caucasians, comprised
of the LCAS subpopulation (N = 333) and the TexGen
subpopulation (N = 451). The study design and the main
results of the LCAS have been published [21]. In brief, the
main LCAS included 372 Caucasians who had at least 1
coronary lesion causing 30% to 75% luminal diameter
stenosis on quantitative coronary angiography and had a
plasma low-density lipoprotein-cholesterol (LDL-C) level
of 115 to 190 mg/dl despite diet. DNA samples from 333
Caucasians were available. The baseline values of plasma
total cholesterol, LDL-C, HDL-C, triglyceride (TG) and
apolipoprotein levels were measured in all participants at
the baseline. Quantitative indices of severity of coronary
atherosclerosis were measured in 289 participants.
Given the relatively small sample size of the LCAS popu-
lation, we recruited 451 patients from outpatient clinics
(the TexGen study). The TexGen subpopulation was
matched for age and the mean plasma HDL-C level to the
LCAS subpopulation. Because of the small number of
females in the LCAS population, we included relatively
more females in the TexGen subpopulation. Individuals
taking medications with direct effects on plasma HDL-C
levels, such as niacin and fibrates were not included in the
study. Those with advanced co-morbid conditions,
including malignancies, advanced heart failure or valvular
heart disease were not included. Demographic data were
collected and fasting plasma total cholesterol, HDL-C,
LDL-C and TG levels were measured in all TexGen partic-
ipants.
Selection of the candidate genes and SNPs
We selected the candidate genes based on a prior knowl-
edge of their involvement in pathways leading to synthe-
sis, maturation, or catabolism of HDL-C in humans or in
experimental animals. Upon selection of the candidate
genes, we searched the SNP database (dbSNP Build 129)
to identify non-synonymous SNPs and the regulatory
SNPs in the 5' or 3' regions of the genes of interest. We
included only SNPs that have been validated, have a
known minor allele frequency (MAF) in the database or
were previously shown to be associated with plasma HDL-
C levels. Given the size of the study population, we mostly
selected the SNPs that had known minor allele frequen-
cies (MAFs) of > 0.1, while realizing that the MAFs could
differ in our study population. In view of the presence of
a very large number of SNP in each gene locus, the
selected SNPs comprised only a fraction of the total SNPs
in the candidate genes loci. We genotyped the selected
SNPs by fluorogenic 5' nucleotidase (Taqman) assays
using an ABI PRISM® 7900HT Real-Time PCR instrument.
The PCR conditions were 1 cycle at 95°C for 10 min, fol-
lowed by 40 cycles at 92°C for 15 sec and 60°C for 1 min
as recommended by the manufacturer (Applied Biosys-
tems, Foster City, CA). Investigators who had no knowl-Page 2 of 8
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genotyping.
Since there was no known candidate SNP in ATP5B, a high
affinity HDL-C receptor for apo A-I [22], we sequenced its
entire coding region, 3' untranslated sequence and a 2 kbp
5' genomic fragment in 50 randomly selected individuals
from the LCAS subpopulation. We performed the
sequencing using the Big Dye Terminator Cycle Sequenc-
ing Ready Reaction Kit on an ABI Genetic Analyzers in
sense and anti-sense directions. The sequences were ana-
lyzed and "Blasted" against the genome databases.
Statistical analysis
We expressed the parametric variables as mean ± SD and
tested the variables for Gaussian distribution by the Sha-
piro-Wilk normality test. We tested the distribution of
genotypes of each SNP for departure of the Hardy-Wein-
berg equilibrium (HWE) by the X2 test using a web-based
program http://www.oege.org/software/hwe-mr-
calc.shtml[23]. We compared the mean values between
the two groups by the t test and analyzed the non-para-
metric variables by the Fisher exact test. We assigned indi-
cators to genotypes as 0, 1 and 2 to represent 0, 1 and 2
copies of the common allele (additive genetic model).
Likewise, we assigned indicators 0 and 1 to females and
males, respectively. Since the distributions of plasma
HDL-C and apo A-I levels deviated significantly from nor-
mality, we analyzed associations between the predictors
and plasma HDL-C and apo A-I levels by Box-Cox regres-
sion analysis using likelihood ratio tests (16,000 itera-
tions). We analyzed each potential predictor separately
and included those with p values ≤ 0.10 in the multivari-
ate Box-Cox regression analysis to determine independent
association of the predictors with the phenotypes. We cal-
culated the False positive Discovery Rate (FDR) for the
results of multivariate analysis by calculating the q values
by the method of Storey and Tibshirani [24]. All statistical
analyses were performed using STATA, IC 10.1 for Macin-
tosh.
Results
Characteristics of the study population
The baseline characteristics of the study population
including the characteristics of the LCAS and TexGen sub-
populations are shown in Table 1. The subpopulations
were matched for age and mean plasma HDL-C levels.
There were more females and more individuals with dia-
betes mellitus in the TexGen subpopulation. There were
modest albeit statistically significant differences in body
weight (~3.4 Kg), body mass index (BMI, ~1.2 Kg/m2),
mean systolic or diastolic blood pressure (1-3 mmHg)
and the history of myocardial infarction between the two
subpopulations (Table 1).
As would be expected, mean plasma HDL-C levels were
similar between the two groups. However, plasma total
cholesterol and LDL-C levels were significantly higher in
the LCAS subpopulations, as a high plasma LDL-C level
was a requirement for inclusion in the LCAS. Plasma apol-
ipoprotein levels and quantitative indices of severity of
coronary atherosclerosis were available only in the LCAS
subpopulation (Table 1).
Candidate genes and SNPs
The list of biologically plausible candidate genes and
SNPs analyzed in the present study and the MAFs in the
entire population are shown in Additional File 1. The gen-
otypes of all but 3 SNPs followed the HWE. The genotypes
of SNPs rs4301822 in APOF, rs2306985 in MTP and
rs2038068 in PPARD showed significant departure from
the HWE (p < 0.05). The departure may reflect genotyping
errors or the population genetic structure. Therefore, they
were not included in the subsequent association analyses.
Independent predictors of plasma HDL-C levels
Plasma HDL-C and apo A-I deviated significantly from the
normal Gaussian distributions (z = 8.473, p < 0.00001 for
HDL-C and z = 6.386, p < 0.00001). Likewise, the log10
transformed HDL-C levels were non-normally distributed
(z = 2.360, p = 0.00913). Therefore, Box-Cox regression
analysis was used to determine association of the poten-
tial predictors with plasma HDL-C and apo A-I levels. Sex,
body mass index (BMI), diabetes mellitus (DM) and ciga-
rette smoking were independent predictors of plasma
HDL-C and apoA-I levels (Tables 2 and 3). The FDR for
each of the observed associations of sex, BMI, DM and
smoking all were very low (less than 0.1%). Therefore,
they were included in the subsequent analyses as covari-
ates.
We genotyped the study population for 94 SNPs in 42
genes (Additional File 1). Three SNPs were very rare and 2
not detected in the LCAS subpopulation. Therefore, we
analyzed 89 SNPs in the entire population and included
any potentially significance association, defined as p <
0.05, in the multivariate analysis. SNPs in APOA5,
APOC2, CETP, LIPC and LPL were independent predictors
of plasma HDL-C levels (Table 4). The FDR for each of the
above genes was ≤ 1 percent. Considering that plasma
HDL-C, DM and BMI may share common genetic etiology
as part of the metabolic syndrome; we repeated the Box-
Cox regression analysis after removal of BMI and DM
from the analysis as covariates. The results, shown in
Table 2, identify APOA2 and SOAT2 variants, in addition
to SNPs in APOA5, APOC2, CETP, LIPC and LPL also as
independent determinants of plasma HDL-C levels.
We also determined independent association of SNPs
with plasma HDL-C levels as a non-parametric phenotypePage 3 of 8
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logistic regression analysis (robust method). The results
were largely concordant with the results of Box-Cox
regression analysis, as sex, BMI, DM and smoking as well
as SNPs in APOA5, CETP and LPL were independent pre-
dictors of plasma HDL-C levels (all q values ≤ 0.06).
Since plasma triglyceride and HDL-C levels may share
common genetic determinants, we analyzed the associa-
tion of plasma triglyceride levels with the demographic
variables and SNPs in APOA5, APOC2, CETP, LIPC and
LPL. We used Box-Cox regression for the analysis because
of non-normal distribution of plasma triglyceride levels.
The main determinants of plasma triglyceride levels in the
present study population were BMI and LPL variants,
Table 1: Baseline Characteristic of the Study Population and Subpopulations
All LCAS TexGen p
N 784 333 451 ---
Demographics
Age (years) 59.3 ± 11.0 59.3 ± 7.7 59.2 ± 13.2 0.527
Male/Female (%) 586/198 (75/25) 281/52 (84/16) 305/146 (68/32) <0.001
Height (m) 1.73 ± 0.09 1.74 ± 0.08 1.73 ± 0.10 0.328
Body weight (Kg) 86.8 ± 18.8 84.9 ± 15.6 88.3 ± 20.7 0.006
Body mass index (Kg/m2) 28.8 ± 5.5 28.1 ± 4.5 29.3 ± 6.1 0.001
Systolic blood pressure (mmHg) 125.9 ± 19.3 124.5 ± 15.3 127.1 ± 21.8 0.029
Diastolic blood Pressure (mmHg) 75.8 ± 11.9 76.7 ± 8.8 75.1 ± 13.7 0.028
Diabetes mellitus (%) 117 (14.5) 11 (3.3) 106 (23.5) <0.001
Smoker (%) 137 (17.5) 68 (20) 69 (15) 0.071
History of myocardial infarction (%) 289 (36.9) 131 (39) 158 (35) <0.001
Plasma Lipids levels
TC (mg/dl) 200.1 ± 56.5 220.0 ± 24.5 185.2 ± 68.0 <0.001
HDL-C (mg/dl) 43.8 ± 13.9 43.8 ± 11.3 43.8 ± 15.5 0.671
LDL-C (mg/dl) 123.9 ± 46.9 143.9 ± 19.9 107.5 ± 55.1 <0.001
LDL-C/HDL-C 3.02 ± 1.28 3.49 ± 0.91 2.65 ± 1.40 <0.001
Triglyceride (mg/dl) 169.7 ± 154.8 161.5 ± 57.1 175.8 ± 198.0 0.101
Plasma apolipoprotein levels (LCAS only)
N 333
Apolipoprotein A-I 132.7 ± 27.4
Apolioprotein B 134.4 ± 20.8
Apolipoprotein B/Apolioprotein A-I 1.05 ± 0.26
Apolipoprotein C-III 35.2 ± 32.8
Quantitative indices of severity of coronary atherolosclerosis (LCAS only)
N 289
Average baseline MLD (mm) 1.68 ± 0.40
Mean number of coronary lesions 2.99 ± 1.38
Number of subject with ≥ two coronary lesion (%) 241 (83%)
Mean number of coronary occlusions 0.29 ± 0.55
Number of subject with ≥ one coronary 72 (25%)
Abbreviations: m: meter; Kg: Kilogram; mmHg: millimeter mercury; mg/dl: milligram per deciliter; TC: Total cholesterol; HDL-C: High-density 
lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; MLD: minimal lumen diameter.
Table 2: Independent Predictors of Median Plasma HDL-C 
Levels Excluding BMI and DM as Co-variates (N = 784)
Predictors Coefficient X2 p Q
Sex (Female = 0, Male = 1) -0.271 91.873 <0.001 <0.001
Smoking (Yes = 1, No = 0) -0.118 14.432 <0.001 <0.001
Gene SNP Coefficient X2 p Q
CETP rs12149545 0.082 20.727 <0.001 <0.001
LPL rs328 0.094 10.870 0.001 0.004
APOA5 rs3135506 -0.145 8.729 0.003 0.008
APOA2 rs3829793 .213 8.259 0.004 0.009
rs3813627 -0.202 7.207 0.007 0.013
LIPC rs36041167 -0.088 5.965 0.015 0.024
APOC2 rs228911 0.041 5.544 0.019 0.026
SOAT2 rs2272296 0.055 4.538 0.033 0.040
Abbreviations: as in Table 2; SOAT2: Sterol O-acyltransferase 2
Table 3: Independent Predictors of Median Plasma apo A-I 
Levels (N = 333)
Predictors Coefficient X2 P q
Sex (Female = 0, Male = 1) -0.0271 79.986 <0.001 <0.001
BMI (Kg/m2) -0.0012 27.609 <0.001 <0.001
Age (years) 0.0005 15.116 <0.001 <0.001
Gene SNP Coefficient X2 P q
MTP rs17029215 0.0045 10.655 0.001 0.005
CETP rs12149545 0.0042 7.852 0.005 0.018
rs58821 0.0035 4.525 0.033 0.066
APOC2 rs228911 0.0036 5.875 0.015 0.034
APOA5 rs3135506 -0.0118 6.797 0.009 0.027
SCARB1 rs8388843 0.0040 6.497 0.011 0.028
Abbreviations: as in the previous TablesPage 4 of 8
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sented).
Independent predictors of plasma apo A-I levels
Plasma apo A-I levels also did not follow a normal distri-
bution. Therefore, we tested the association of plasma apo
A-I levels with demographic predictors and SNP by Box-
Cox regression. Sex (higher in females), BMI (inversely),
age (positively) and SNPs in MTP, CETP, APOC2, APOA5
and SCARB1 were independent predictors of plasma apo
A-I levels (Table 3).
SNPs and severity of coronary atherosclerosis
There was no significant association between the demo-
graphic variables and the severity of coronary atheroscle-
rosis at the baseline. However, baseline MLD was
associated with the rs3135506 (S19W) SNP in APOA5.
Those with the uncommon allele (GA only, no AA) had
more severe coronary atherosclerosis than those with the
common genotype (GG). The mean MLD was 1.42 ± 0.43
mm in those with the GA genotype (N = 11) and 1.69 ±
0.69 (N = 278) in those with the GG genotype (t = 2.204,
p = 0.014, q = 0.021). Likewise, the number of coronary
occlusion was greater in those with the GA as compared to
those with the GG genotype (0.064 ± 0.67 vs. 0.28 ± 0.54,
respectively, p = 0.034). It merits noting that the observed
association with the severity of coronary artery disease
was concordant with the effects of the SNP on plasma
HDL-C (~6 mg/dl lower in those with GA genotype) and
apo A-I (~13 mg/dl lower in those with the GA genotype)
levels. The MTP variants (rs2306986) were also associated
with the MLD at the baseline. The mean MLD was 1.66 ±
0.40 mm in individuals with the GG genotype (N = 273)
as compared to 1.94 ± 0.34 mm in those with the GC gen-
otype (N = 16, t = -2.8084, p = 0.0027, q = 0.008).
SNPs and progression of coronary atherosclerosis
Plasma levels of HDL-C (regression coefficient: 0.004,
95% CI: [0.002-0.006], t = 3.36, p = 0.001) and treatment
with fluvastatin (regression coefficient: 0.084, 95% CI:
[0.032-0.136], t = 3.19, p = 0.002) were independent pre-
dictors of the progression of coronary atherosclerosis
(change in MLD) in the LCAS population [21]. Therefore,
we included HDL-C levels and treatment with fluvastatin
as covariates in the genetic analysis. Progression of coro-
nary atherosclerosis as determined by the change in MLD
during the 2.5 years follow up, was associated with S19W
SNP in APOA5. Those with the uncommon genotype
(AG) had greater loss of MLD (0.25 ± 0.23 mm) over the
follow up period than those with the common genotype
(-0.05 ± 0.25 mm, p = 0.0048).
Discussion
We analyzed association of plasma HDL-C levels with 89
putatively functional SNPs in 42 biologically candidate
genes in a well-characterized Caucasian population. The
results show that SNPs in genes encoding apo A-II
(APOA2) apo A-V (APOA5), apo C-II (APOC2), choles-
teryl ester transfer protein (CETP), hepatic lipase (LIPC),
lipoprotein lipase (LPL) and Sterol O-acyltransferase 2
(SOAT2) as well as demographic variables sex, BMI, DM
and smoking were independent predictors of plasma
HDL-C levels. The false positive discovery rates (q values)
for the observed associations were less than 5%, which is
considered low. Consistent with the above, SNPs in CETP,
APOC2 and APOA5 were also independent predictors of
plasma apo A-I levels. Likewise, the APOA5 variant was
also associated with the severity of coronary atherosclero-
sis at the baseline as well as progression of coronary
atherosclerosis over a 2.5 years period.
The results of the present study are largely in accord with
the known biological effects of the genes in HDL-C bio-
synthesis, maturation and catabolism and largely sup-
ported by the previous data for SNPs in APOA5, CETP,
LIPC and LPL genes [20,25-31]. An interesting finding was
the concordant association of the S19W SNP in APOA5
with plasma HDL-C and apo A-I levels as well as the sever-
ity of coronary atherosclerosis and its progression. APOA5
encodes apo A-V, which is a component of HDL-C and an
important determinant of plasma triglyceride levels. The
APOA5 S19W variant has been previously associated with
Table 4: Independent Predictors of Median Plasma HDL-C Levels (N = 784)
Predictors Coefficient X2 p Q
Sex (Female = 0, Male = 1) -0.327 102.294 <0.001 <0.001
BMI (Kg/m2) -0.015 34.576 <0.001 <0.001
DM (Yes = 1, No = 0) -0.224 33.335 <0.001 <0.001
Smoking (Yes = 1, No = 0) -0.153 17.824 <0.001 <0.001
Gene SNP Coefficient X2 p Q
CETP rs12149545 0.121 11.566 0.001 0.003
LPL rs328 0.101 9.903 0.002 0.005
APOC2 rs228911 0.057 8.239 0.004 0.008
APOA5 rs3135506 -0.150 7.206 0.007 0.012
LIPC rs36041167 -0.110 7.144 0.008 0.012
Abbreviations: BMI: Body mass index; DM: Diabetes mellitus. CETP: Cholesteryl Ester Transfer; LPL: Lipoprotein Lipase; APOC2: Apolipoprotein 
C-II; APOA5: Apolipoprotein A-V; LIPC: Hepatic LipasePage 5 of 8
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[19,32]. However, the findings regarding the associations
of the S19W SNP with the severity and progression of cor-
onary atherosclerosis are new and in harmony with the
effects of the APOA5 variants on plasma HDL-C, apo A-I
and triglyceride levels. Thus, the findings further substan-
tiate the clinical significance of APOA5 variants in coro-
nary atherosclerosis.
The observed associations of plasma HDL-C and apo A-I
levels with APOC2 variants are also novel, albeit intrinsic
to the candidate gene approach is a prior biological plau-
sibility of the candidates and hence, the findings were not
unexpected. Apo C-II is an activator of lipoprotein lipase
(LPL) and a regulator of plasma triglyceride levels. Loss-
of-function mutations in APOC2 and LPL are associated
with severe hypertriglyceridemia [33]. As in the present
study, variants of LPL have been previously associated
with plasma HDL-C levels [34].
Association studies that include multiple SNPs have an
inherent risk of spurious associations. To shed some light
on the possibility of association by chance alone, we cal-
culated the FDR. We note the FDR for the above associa-
tions between plasma HDL-C and SNPs were quite low (q
values of ≤ 0.01). Equally striking is the absence of signif-
icant associations between plasma HDL-C levels and
SNPs in many of the selected genes that have been previ-
ously implicated - through studies in humans or animals
- in HDL-C biosynthesis and metabolism. Various factors
may contribute to the null results for the above genes
including the characteristics of the study population,
competing factors (demographic predictors), and con-
servative approach to analysis as well as the possibility of
type II statistical error. The latter is typically due to inter-
play between the sample size of the study population, fre-
quencies of the alleles and the effect sizes. Despite our a
prior focus on common SNPs, the MAFs of 18 SNPs in our
study population were <0. 05. Unless the uncommon alle-
les impart major effects on the plasma HDL-C levels,
detection of a significant association would require a
much larger population. Nevertheless, at an MAF of 0.05,
assuming Hard-Weinberg equilibrium, the sample size of
the study population provided 85% power to detect a 5
mg/dl difference in the mean plasma HDL-C levels
between the common and uncommon genotypes, when α
is set at 0.05. A larger sample size would be required to
detect a smaller effect or the effects of even less frequent
alleles. Likewise, we note that the secondary findings in
the present study, namely, the observed associations
between SNPs and the quantitative indices of severity of
coronary atherosclerosis merit testing for replications.
Finally, the study population was comprised of self-
described Caucasians, which may not represent a geneti-
cally homogenous population. Hence, the results may be
subject to possible population stratification.
The study is by no means comprehensive of all known
genes and SNPs with possible roles in the HDL-C biosyn-
thesis, maturation, conversion and/or catabolism.
Recently SNPs in GALNT2, which encodes N-actetylgalac-
tosaminyltransferase 2 locus were shown to be associated
with plasma HDL-C and triglyceride levels in GWAS
[19,35]. Similarly, SNPs at the MMAB/MVK locus, which
encode mevalonate kinase and methylmalonic aciduria
cblB type, respectively have also been associated with
plasma HDL-C levels [20]. SNPs in VNN1 encoding
pantetheinase or vannin 1 have also been associated with
plasma HDL-C levels [36]. Additional genes in animal
models also have been associated with plasma HDL-C lev-
els, such as Sirt1, encoding sirtuin 1 [37]. We did not
include these new genes primarily because their func-
tional roles in HDL-C biosynthesis and metabolism have
not yet been determined.
Conclusion
We genotyped 784 Caucasian individuals for 94 candidate
functional SNPs in 42 biologically plausible candidate
genes implicated in HDL-C biosynthesis and metabolism.
We report that SNPs in APOA2, APOA5, APOC2, CETP,
LIPC and LPL are independent determinants of plasma
HDL-C levels. SNPs in APOA5 are also associated with
plasma apo A-I level, severity of coronary atherosclerosis
as well as its progression.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SNC carried out genotyping and assisted in data analysis,
MC performed DNA sequencing and genotyping, JT car-
ried out genotyping, RL also carried out genotyping and
participated in phenotyping, JTW conceived and coordi-
nated the TexGen study and recruited patients, AMG con-
ceived, designed and coordinated the Lipoprotein and
Coronary Atherosclerosis Study, CMB participated in the
design of the study and phenotyping of the Lipoprotein
and Coronary Atherosclerosis Study population and AJM
conceived the genetic studies, analyzed the data and wrote
the manuscript.
All authors read and approved the final manuscript.
Additional material
Additional file 1
List of Candidate Genes and Putative Functional SNPs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2350-10-111-S1.pdf]Page 6 of 8
(page number not for citation purposes)
BMC Medical Genetics 2009, 10:111 http://www.biomedcentral.com/1471-2350/10/111Acknowledgements
Supported in part by grants from the TexGen Foundation and McDonald 
General Research Fund
References
1. Lopez AD, Murray CC: The global burden of disease, 1990-
2020.  NatMed 1998, 4:1241-1243.
2. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J,
Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ: Famil-
ial lipoprotein disorders in patients with premature coro-
nary artery disease.  Circulation 1992, 85:2025-2033.
3. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH,
Schein JR, Gotto AM Jr: Influence of low HDL on progression of
coronary artery disease and response to fluvastatin therapy.
Circulation 1999, 99:736-743.
4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Hut-
tunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart
Study: primary-prevention trial with gemfibrozil in middle-
aged men with dyslipidemia. Safety of treatment, changes in
risk factors, and incidence of coronary heart disease.  N Engl J
Med 1987, 317:1237-1245.
5. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR,
Kjekshus J: Influence of low high-density lipoprotein choles-
terol and elevated triglyceride on coronary heart disease
events and response to simvastatin therapy in 4S.  Circulation
2001, 104:3046-3051.
6. Goldbourt U, Yaari S, Medalie JH: Isolated Low HDL Cholesterol
As a Risk Factor for Coronary Heart Disease Mortality: A 21-
Year Follow-up of 8000 Men.  Arteriosclerosis, Thrombosis, and Vas-
cular Biology 1997, 17:107-113.
7. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC,
Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, et
al.: Relation of gemfibrozil treatment and lipid levels with
major coronary events: VA-HIT: a randomized controlled
trial.  JAMA: The Journal of the American Medical Association 2001,
285:1585-1591.
8. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D,
Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ: Reduc-
tion in Stroke With Gemfibrozil in Men With Coronary
Heart Disease and Low HDL Cholesterol: The Veterans
Affairs HDL Intervention Trial (VA-HIT).  Circulation 2001,
103:2828-2833.
9. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS,
Dowdy AA, Marino EK, Bolson EL, Alaupovic P, et al.: Simvastatin
and Niacin, Antioxidant Vitamins, or the Combination for
the Prevention of Coronary Disease.  The New England Journal Of
Medicine 2001, 345:1583-1592.
10. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda
M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al.: Effects of
Torcetrapib in Patients at High Risk for Coronary Events.
The New England Journal Of Medicine 2007, 357:2109-2122.
11. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam
M, Yu L, Brewer C, Collins JA, Molhuizen HO, et al.: Mutations in
ABC1 in Tangier disease and familial high-density lipopro-
tein deficiency.  NatGenet 1999, 22:336-345.
12. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich
W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, et al.:
The gene encoding ATP-binding cassette transporter 1 is
mutated in Tangier disease.  NatGenet 1999, 22:347-351.
13. Mathias RA, Roy-Gagnon MH, Justice CM, Papanicolaou GJ, Fan YT,
Pugh EW, Wilson AF: Comparison of year-of-exam- and age-
matched estimates of heritability in the Framingham Heart
Study data.  BMCGenet 2003, 4(Suppl 1):S36.
14. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz
RR, Roman MJ, MacCluer JW: Genetic and environmental con-
tributions to cardiovascular disease risk in American Indians:
the strong heart family study.  American Journal of Epidemiology
2003, 157:303-314.
15. Perusse L, Rice T, Despres JP, Bergeron J, Province MA, Gagnon J,
Leon AS, Rao DC, Skinner JS, Wilmore JH, et al.: Familial resem-
blance of plasma lipids, lipoproteins and postheparin lipopro-
tein and hepatic lipases in the HERITAGE Family Study.
ArteriosclerThrombVascBiol 1997, 17:3263-3269.
16. Brenn T: Genetic and environmental effects on coronary
heart disease risk factors in northern Norway. The cardio-
vascular disease study in Finnmark.  AnnHumGenet 1994, 58(Pt
4):369-379.
17. Namboodiri KK, Kaplan EB, Heuch I, Elston RC, Green PP, Rao DC,
Laskarzewski P, Glueck CJ, Rifkind BM: The Collaborative Lipid
Research Clinics Family Study: biological and cultural deter-
minants of familial resemblance for plasma lipids and lipo-
proteins.  GenetEpidemiol 1985, 2:227-254.
18. Rao DC, Laskarzewski PM, Morrison JA, Khoury P, Kelly K, Wette R,
Russell J, Glueck CJ: The Cincinnati Lipid Research Clinic fam-
ily study: cultural and biological determinants of lipids and
lipoprotein concentrations.  AmJHumGenet 1982, 34:888-903.
19. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ,
Cooper GM, Roos C, Voight BF, Havulinna AS, et al.: Six new loci
associated with blood low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol or triglycerides in
humans.  Nat Genet 2008, 40:189-197.
20. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R,
Heath SC, Timpson NJ, Najjar SS, Stringham HM, et al.: Newly iden-
tified loci that influence lipid concentrations and risk of cor-
onary artery disease.  Nat Genet 2008, 40:161-169.
21. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West
MS, Gould KL, Gotto AM Jr: Effects of fluvastatin on coronary
atherosclerosis in patients with mild to moderate choles-
terol elevations (Lipoprotein and Coronary Atherosclerosis
Study [LCAS]).  AmJCardiol 1997, 80:278-286.
22. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne
E, Pineau T, Georgeaud V, Walker JE, Terce F, et al.: Ectopic beta-
chain of ATP synthase is an apolipoprotein A-I receptor in
hepatic HDL endocytosis.  Nature 2003, 421:75-79.
23. Rodriguez S, Gaunt TR, Day IN: Hardy-Weinberg equilibrium
testing of biological ascertainment for Mendelian randomi-
zation studies.  Am J Epidemiol 2009, 169:505-514.
24. Storey JD, Tibshirani R: Statistical significance for genomewide
studies.  ProcNatlAcadSci USA 2003, 100:9440-9445.
25. de Grooth GJ, Zerba KE, Huang SP, Tsuchihashi Z, Kirchgessner T,
Belder R, Vishnupad P, Hu B, Klerkx AHEM, Zwinderman AH: The
cholesteryl ester transfer protein (CETP) TaqIB polymor-
phism in the cholesterol and recurrent events study: no
interaction with the response to pravastatin therapy and no
effects on cardiovascular outcome: A prospective analysis of
the CETP TaqIB polymorphism on cardiovascular outcome
and interaction with cholesterol-lowering therapy.  Journal of
the American College of Cardiology 2004, 43:854-857.
26. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, Ruidavets JB,
Arveiler D, Luc G, Tiret L, Cambien F: Extensive association anal-
ysis between the CETP gene and coronary heart disease
phenotypes reveals several putative functional polymor-
phisms and gene-environment interaction.  GenetEpidemiol
2000, 19:64-80.
27. Yamada Y, Matsuo H, Warita S, Watanabe S, Kato K, Oguri M, Yokoi
K, Metoki N, Yoshida H, Satoh K, et al.: Prediction of genetic risk
for dyslipidemia.  Genomics 2007, 90:551-558.
28. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, Brunzell JD: Contribu-
tion of hepatic lipase, lipoprotein lipase, and cholesteryl
ester transfer protein to LDL and HDL heterogeneity in
healthy women.  ArteriosclerThrombVascBiol 2002, 22:667-673.
29. Couture P, Otvos JD, Cupples LA, Lahoz C, Wilson PW, Schaefer EJ,
Ordovas JM: Association of the C-514T polymorphism in the
hepatic lipase gene with variations in lipoprotein subclass
profiles: The Framingham Offspring Study.  ArteriosclerThromb-
VascBiol 2000, 20:815-822.
30. Deeb SS, Peng R: The C-514T polymorphism in the human
hepatic lipase gene promoter diminishes its activity.  J Lipid
Res 2000, 41:155-158.
31. Dugi KA, Brandauer K, Schmidt N, Nau B, Schneider JG, Mentz S,
Keiper T, Schaefer JR, Meissner C, Kather H, et al.: Low hepatic
lipase activity is a novel risk factor for coronary artery dis-
ease.  Circulation 2001, 104:3057-3062.
32. Wang J, Ban MR, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL,
Hegele RA: APOA5 genetic variants are markers for classic
hyperlipoproteinemia phenotypes and hypertriglyceri-
demia.  Nat Clin Pract Cardiovasc Med 2008, 5:730-737.
33. Connelly PW, Maguire GF, Hofmann T, Little JA: Structure of apol-
ipoprotein C-IIToronto, a nonfunctional human apolipopro-
tein.  Proc Natl Acad Sci USA 1987, 84:270-273.Page 7 of 8
(page number not for citation purposes)
BMC Medical Genetics 2009, 10:111 http://www.biomedcentral.com/1471-2350/10/111Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
34. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C,
Hirschhorn JN, Berglund G, Hedblad B, Groop L, et al.: Polymor-
phisms associated with cholesterol and risk of cardiovascular
events.  N Engl J Med 2008, 358:1240-1249.
35. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMa-
hon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, et al.:
Cholesteryl Ester Transfer Protein TaqIB Variant, High-
Density Lipoprotein Cholesterol Levels, Cardiovascular
Risk, and Efficacy of Pravastatin Treatment: Individual
Patient Meta-Analysis of 13 677 Subjects.  Circulation 2005,
111:278-287.
36. Goring HHH, Curran JE, Johnson MP, Dyer TD, Charlesworth J, Cole
SA, Jowett JBM, Abraham LJ, Rainwater DL, Comuzzie AG, et al.: Dis-
covery of expression QTLs using large-scale transcriptional
profiling in human lymphocytes.  Nat Genet 2007, 39:1208-1216.
37. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L: SIRT1
Deacetylates and Positively Regulates the Nuclear Receptor
LXR.  Molecular Cell 2007, 28:91-106.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/111/pre
pubPage 8 of 8
(page number not for citation purposes)
